In recent years, the combination of Dasatinib + Quercetin (D+Q) has become a star in the senolytic field. Studies have shown it successfully eliminates zombie cells in culture and improves function in whole organisms. It has entered clinical trials for lung diseases, kidney diseases, diabetes, and general frailty. But a new study published in the scientific journal PNAS (Proceedings of the National Academy of Sciences), one of the most prestigious and peer-reviewed journals in science, raises a serious warning: D+Q may cause brain damage.
What are Dasatinib and Quercetin?
The two drugs work in combination:
- Dasatinib: An oncology drug approved for treating leukemia. It inhibits several enzymes that cancer cells need to survive
- Quercetin: A flavonoid found in onions, apples, and other fruits and vegetables. It is widely studied as a dietary supplement
In combination, they attack the "defense pathways" of zombie cells in several different ways, causing them to die. They are considered the gold standard of senolytics, which is why they are in many clinical trials.
The New Study
A team led by researchers Evan R. Lombardo and Robert S. Pijewski, working under senior researcher Prof. Stephen J. Crocker from the University of Connecticut School of Medicine (UConn), conducted an eye-opening experiment. The researchers essentially hoped that D+Q would help repair brain damage, but they discovered the opposite. They treated two groups of mice, young (6 to 9 months old) and old (22 months old), gave them D+Q, and examined what happened in the brain. The findings were troubling:
- Oligodendrocyte cells functioned less. These are the cells that produce myelin, the substance that wraps around neurons and enables fast nerve signal transmission
- Less myelin in the corpus callosum. That is, the insulating layer around nerve fibers in the area connecting the two brain hemispheres was reduced
- The cells did not die, but regressed to an immature state. Instead of dying, the oligodendrocyte cells returned to a kind of young, immature state, lost their complexity, and could no longer lay down myelin properly
The most surprising finding: the damage was more severe in young mice, not old ones. This result is particularly troubling because it shows that the harm is not dependent on old age, and that a healthy, young brain system can also be affected.
Additionally, the researchers noted that the abnormal oligodendrocyte cells that formed resembled a specific cell population previously identified in the brains of multiple sclerosis (MS) patients, an autoimmune disease characterized by myelin loss. That is, it is a similarity in cell state, not the appearance of the disease symptoms themselves.
Why Does This Happen?
The researchers suggest several possible mechanisms:
- Healthy oligodendrocyte cells are damaged. It is possible that D+Q does not distinguish well enough between zombie cells and other healthy cells, also causing healthy cells to be harmed
- Metabolic damage. It is possible that the drugs disrupt energy availability in cells, pushing them to regress to an immature state
- A side effect that appears quickly. In culture, the effect on cell morphology was seen within minutes, and in mice it was measured as early as one month after starting treatment
What Does This Mean for Clinical Trials?
The senolytic D+Q is currently being tested in clinical trials for:
- Alzheimer's and cognitive decline
- Pulmonary fibrosis
- Chronic kidney disease
- Frailty and osteoarthritis
- Diabetes
Human trials so far have been small and early, and they have not specifically examined white matter and myelin in the brain. That is, even if no brain damage has been reported so far, it is possible that it simply was not looked for in the right place. This study suggests: more careful examination of brain function is required in any future D+Q trial.
What Does This Mean for You?
If you are taking D+Q:
- As part of a clinical trial: Ask your doctor to examine cognitive function, brain MRI if possible. Report any changes in memory, vision, or coordination
- On an experimental basis: Consider stopping until further human studies are published. The risk according to the new study has not yet been directly tested in humans, but it is being investigated now
- Regardless: Consult a neurologist or primary care physician before starting any senolytic protocol
The Broader Context
This study is an example of what happens when a young field tries to move to the clinic too early. Senolytics are a huge promise, but we are only at the beginning of the road. Discoveries like this remind us that drugs that work in mice do not always work in humans, and that treatments that work on one organ can harm another.
The Bottom Line
D+Q is not a bad drug. It is simply not precise enough yet. New generations of senolytics are in development, for example an approach targeting GPX4 that eliminates zombie cells through a process called ferroptosis (as recently reported in the journal Nature Cell Biology), but there is still no direct comparison showing these are safer for the brain. In the meantime, if you are interested in senolytics, the safest way is: regular physical activity, controlled intermittent fasting, and a Mediterranean diet. All of these naturally reduce senescent burden.
💬 Comments (0)
Be the first to comment on the article.